Cholangiolocellular Carcinoma With “Ductal Plate Malformation” Pattern May Be Characterized by ARID1A Genetic Alterations
暂无分享,去创建一个
[1] H. Seno,et al. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. , 2018, Gastroenterology.
[2] Kathryn J Fowler,et al. cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation , 2018, Hepatology.
[3] Baofeng Lian,et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[4] M. Fassan,et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma , 2018, Scientific Reports.
[5] G. Getz,et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. , 2018, Journal of hepatology.
[6] A. Luciani,et al. Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.
[7] Bin Tean Teh,et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. , 2017, Cancer discovery.
[8] L. Wood,et al. PBRM1 loss is a late event during the development of cholangiocarcinoma , 2017, Histopathology.
[9] Y. Pomyen,et al. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. , 2017, Cancer cell.
[10] Ke Hao,et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. , 2017, Journal of hepatology.
[11] D. Schadendorf,et al. SF3B1 and BAP1 mutations in blue nevus-like melanoma , 2017, Modern Pathology.
[12] Yasunori Sato,et al. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance , 2017, Histopathology.
[13] Yasunori Sato,et al. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. , 2016, American journal of clinical pathology.
[14] Hiromi Nakamura,et al. Genomic spectra of biliary tract cancer , 2015, Nature Genetics.
[15] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[16] Yasunori Sato,et al. Clinicopathological significance of ‘subtypes with stem‐cell feature’ in combined hepatocellular‐cholangiocarcinoma , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[17] Keith A. Boroevich,et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity , 2015, Nature Communications.
[18] G. Mills,et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.
[19] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[20] L. Wood,et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups , 2014, Oncotarget.
[21] David M. Jones,et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.
[22] Swe Swe Myint,et al. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.
[23] T. Pawlik,et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.
[24] I. Shih,et al. Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma , 2013, The American journal of surgical pathology.
[25] Masakazu Yamamoto,et al. Intrahepatic Cholangiocarcinoma With Predominant “Ductal Plate Malformation” Pattern: A New Subtype , 2012, The American journal of surgical pathology.
[26] Keith A. Boroevich,et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.
[27] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[28] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[29] O. Matsui,et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’ , 2007, Histopathology.
[30] M. Matsuda,et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.
[31] Y. Maehara,et al. Histologic Characteristics and Prognostic Significance in Small Hepatocellular Carcinoma With Biliary Differentiation: Subdivision and Comparison With Ordinary Hepatocellular Carcinoma , 2007, The American journal of surgical pathology.
[32] A. West,et al. Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers , 2004, Hepatology.
[33] K. Tsuneyama,et al. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. , 2003, Human pathology.
[34] K. Chayama,et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis , 2000, Cancer.
[35] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.
[36] P. Steiner,et al. Cholangiolocellular carcinoma of the liver , 1959, Cancer.
[37] M. Choi,et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. , 2005, American journal of surgery.